| Title | [Urology] | | Author(s) | Jichlinski P, Wisard M | | Institution | Service d'urologie, CHUV, 1011 Lausanne. Patrice.Jichlinski@chuv.ch | | Source | Rev Med Suisse 2009 Jan 14; 5(186):144-6. | | Abstract | In prostatic cancer, PSA velocity is a reliable sign of cancer agressivity. In the metastatic prostatic cancer, there is no difference on survival between an early and late hormonal treatment. In the invasive bladder cancer néo-adjuvant chemotherapy offers a light advantage. In the kidney cancer, anti-angiogenic agents increase the survival. In the non neurogenic overactive bladder, no studies have led to relevant results in using antimuscarinic agent in the first line. The 5 phophodiesterase inhibitors used in the treatment of erectile dysfunction are also effective in the treatment of trouble induced by benign prostatic hyperplasia. | | Language | fre | | Pub Type(s) | English Abstract
Journal Article
| | PubMed ID | 19238935 |
|
